Download PDF
Thromb Haemost 2003; 89(04): 705-717
DOI: 10.1055/s-0037-1613577
Cellular Proteolysis and Oncology
Schattauer GmbH

Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer

Thomas Luther
1   Institut für Pathologie, Technische Universität Dresden, Dresden, Germany
,
Matthias Kotzsch
1   Institut für Pathologie, Technische Universität Dresden, Dresden, Germany
,
Axel Meye
2   Klinik für Urologie, Technische Universität Dresden, Dresden, Germany
,
Thomaz Langerholc
3   Klinische Forschergruppe der Frauenklinik, Technische Universität München, Munich, Germany
,
Susanne Füssel
2   Klinik für Urologie, Technische Universität Dresden, Dresden, Germany
,
Natalie Olbricht
3   Klinische Forschergruppe der Frauenklinik, Technische Universität München, Munich, Germany
,
Sybille Albrecht
1   Institut für Pathologie, Technische Universität Dresden, Dresden, Germany
,
Detlev Ockert
4   Klinik für VTG-Chirurgie, Technische Universität Dresden, Dresden, Germany
,
Bernd Muehlenweg
3   Klinische Forschergruppe der Frauenklinik, Technische Universität München, Munich, Germany
,
Katrin Friedrich
1   Institut für Pathologie, Technische Universität Dresden, Dresden, Germany
,
Marianne Grosser
1   Institut für Pathologie, Technische Universität Dresden, Dresden, Germany
,
Manfred Schmitt
3   Klinische Forschergruppe der Frauenklinik, Technische Universität München, Munich, Germany
,
Gustavo Baretton
1   Institut für Pathologie, Technische Universität Dresden, Dresden, Germany
,
Viktor Magdolen
3   Klinische Forschergruppe der Frauenklinik, Technische Universität München, Munich, Germany
› Author Affiliations
Further Information

Publication History

Received 25 October 2002

Accepted after revision 27 December 2003

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

The cellular receptor for urokinase-type plasminogen activator, uPAR, plays a central role in both cell surface-associated proteolysis and cellular adhesion. In the present study, we systematically searched for splice variants of uPAR mRNA in human cells and tumor tissues by qualitative RT-PCR using specific primers for uPAR exons 1 and 6. Beside the wild-type (wt) uPAR mRNA and the previously described splice variant lacking exon 5 (uPAR-del5), a novel splice variant lacking both exons 4 and 5 (uPAR-del4/5) was found predominantly in various cancer cell lines. To elucidate whether alternatively spliced uPAR mRNA may be translated and post-translationally processed, we generated stably transfected Chinese hamster ovary cells, which harbor expression plasmids of wt uPAR and various uPAR variants including uPAR-del5 and uPAR-del4/5. By ELISA, flow cytofluorometry, and Western blot analysis, we confirmed synthesis and secretion of wt uPAR and the uPAR variants by the use of domain-specific monoclonal antibodies against uPAR. For quantification of uPAR mRNA variants, we established two highly sensitive real-time RT-PCR assays based on LightCycler technology. Study of their expression in a representative set of breast cancer tissues indicated that the novel mRNA variant uPAR-del4/5 was expressed very frequently and independently of uPAR mRNA variants covering exon 4 (uPAR-wt and uPAR-del5). Higher uPAR-del4/5 expression was significantly associated with shorter disease-free survival (p = 0.0004) of breast cancer patients. These results suggest that uPAR-del4/5 mRNA may serve as a novel prognostic marker in breast cancer.

Theme paper: Part of this paper was originally presented at the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.

Keywords

Urokinase receptor - cancer - splice variants - mRNA - LightCycler technology
 

  • References

  • 1 Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
    CrossrefPubMedGoogle Scholar
  • 2 Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-5.
    CrossrefPubMedGoogle Scholar
  • 3 Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-33.
    CrossrefPubMedGoogle Scholar
  • 4 Ellis V, Murphy G. Cellular strategies for proteolytic targeting during migration and invasion. FEBS Lett 2001; 506: 1-5.
    CrossrefPubMedGoogle Scholar
  • 5 Magdolen U, Krol J, Sato S, Mueller MM, Sperl S, Krüger A, Schmitt M, Magdolen V. Natural inhibitors of tumor-associated proteases. Radiol Oncol 2002; 36: 131-43.
    PubMedGoogle Scholar
  • 6 Del Rosso M, Fibbi G, Pucci M, D’Alessio S, Del Rosso A, Magnelli L, Chiarugi V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 2002; 19: 193-207.
    CrossrefPubMedGoogle Scholar
  • 7 Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998; 13: 893-906.
    PubMedGoogle Scholar
  • 8 Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther 2001; 1: 683-91.
    CrossrefPubMedGoogle Scholar
  • 9 Sperl S, Mueller MM, Wilhelm OG, Schmitt M, Magdolen V, Moroder L. The uPA/uPAR system as a target for tumor therapy. Drug News Perspect 2001; 14: 401-11.
    CrossrefPubMedGoogle Scholar
  • 10 Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621-8.
    CrossrefPubMedGoogle Scholar
  • 11 Chapman HA, and Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001; 86: 124-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Behrendt N, Rønne E, Ploug M, Petri T, Løber D, Nielsen LS, Schleuning WD, Blasi F, Appella E, Danø K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453-60.
    PubMedGoogle Scholar
  • 13 Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL. et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8: 1132-41.
    PubMedGoogle Scholar
  • 14 Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
    PubMedGoogle Scholar
  • 15 Casey JR, Petranka JG, Kottra J, Fleenor DE, Rosse WF. The structure of the urokinase-type plasminogen activator receptor gene. Blood 1994; 84: 1151-6.
    PubMedGoogle Scholar
  • 16 Pyke C, Eriksen J, Solberg H, Nielsen BS, Kristensen P, Lund LR, Danø K. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett 1993; 326: 69-74.
    CrossrefPubMedGoogle Scholar
  • 17 Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-6.
    PubMedGoogle Scholar
  • 18 Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Müller M, Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Path 1997; 150: 1231-44.
    PubMedGoogle Scholar
  • 19 Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology 2000; 36: 499-504.
    CrossrefPubMedGoogle Scholar
  • 20 Magdolen V, Rettenberger P, Lopens A, Oi H, Lottspeich F, Kellermann J, Creutzburg S, Goretzki L, Weidle UH, Wilhelm O, Schmitt M, Graeff H. et al. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells. Purification of the recombinant proteins and generation of polyclonal antibodies in chicken. Electrophoresis 1995; 16: 813-6.
    CrossrefPubMedGoogle Scholar
  • 21 Schaefer BM, Stark HJ, Fusenig NE, Todd RF, and Kramer MD. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Exp Cell Res 1995; 220: 415-23.
    CrossrefPubMedGoogle Scholar
  • 22 Müller M, and Flössel C. Induktion und Bestimmung prokoagulatorischer Aktivität mononukleärer Zellen desmenschlichen Blutes. Z Med Lab Diagn 1988; 29: 46-52.
    PubMedGoogle Scholar
  • 23 Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, and Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasmino-gen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-30.
    PubMedGoogle Scholar
  • 24 Luther T, Flössel C, Albrecht S, Kotzsch M, and Müller M. Tissue factor expression in normal and abnormal mammary gland. Nature Med 1996; 2: 491-2.
    PubMedGoogle Scholar
  • 25 Lutz V, Reuning U, Krüger A, Luther T, Pildner von Steinburg S, Graeff H, Schmitt M, Wilhelm OG, Magdolen V. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001; 382: 789-98.
    PubMedGoogle Scholar
  • 26 Grosser M, Luther T, Müller J, Schuppler M, Bickhardt J, Matthiessen W, Müller M. Detection of M. tuberculosis DNA in sarcoidosis: correlation with T-cell response. Lab Invest 1999; 79: 775-84.
    PubMedGoogle Scholar
  • 27 Köhler T, Lerche D, Meye A, Weisbrich C, Wagner O. Automated analysis of nucleic acids by quantitative PCR using coated ready-to-use reaction tubes. J Lab Med 1999; 23: 408-14.
    PubMedGoogle Scholar
  • 28 Kotzsch M, Luther T, Harbeck N, Ockert D, Lutz V, Noack F, Grossmann D, Albrecht S, Kramer MD, Lossnitzer A, Grosser M, Schmitt M, Magdolen V. et al. New ELISA for quantification of human urokinase receptor (CD87) in cancer. Int J Oncol 2000; 17: 827-34.
    PubMedGoogle Scholar
  • 29 Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, and Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16: 7279-86.
    CrossrefPubMedGoogle Scholar
  • 30 Ploug M, Rahbek-Nielsen H, Nielsen PF, Roepstorff P, Dano K. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells. J Biol Chem 1998; 273: 13933-43.
    CrossrefPubMedGoogle Scholar
  • 31 Behrendt N, and Stephens RW. The urokinase receptor. Fibrinol Proteol 1998; 12: 191-204.
    CrossrefPubMedGoogle Scholar
  • 32 Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999; 56: 104-32.
    CrossrefPubMedGoogle Scholar
  • 33 Ploug M, Gardsvoll H, Jorgensen TJ, Lonborg Hansen L, Dano K. Structural analysis of the interaction between urokinase-type plasmino-gen activator and its receptor: a potential target for anti-invasive cancer therapy. Biochem Soc Trans 2002; 30: 177-83.
    CrossrefPubMedGoogle Scholar
  • 34 Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243: 21-6.
    CrossrefPubMedGoogle Scholar
  • 35 Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989; 264: 2185-8.
    PubMedGoogle Scholar
  • 36 Ragno P, Montuori N, Covelli B, Høyer-Hansen G, and Rossi G. Differential expression of a truncated form of the urokinase-type plasminogen activator receptor in normal and tumor thyroid cells. Cancer Res 1998; 58: 1315-9.
    PubMedGoogle Scholar
  • 37 Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000; 475: 52-6.
    CrossrefPubMedGoogle Scholar
  • 38 Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 2002; Sep 23 [epub ahead of print 277 (49) 46932-9.
    CrossrefPubMedGoogle Scholar
  • 39 Solberg H, Romer J, Brunner N, Holm A, Sidenius N, Dano K, Hoyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive trans-planted human and murine tumors. Int J Cancer 1994; 58: 877-81.
    CrossrefPubMedGoogle Scholar
  • 40 Riittinen L, Limongi P, Crippa MP, Conese M, Hernandez-Marrero L, Fazioli F, Blasi F. Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity. FEBS Lett 1996; 381: 1-6.
    CrossrefPubMedGoogle Scholar
  • 41 Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van MEGelder, Henzen-Logmans SC, van Putten WL, Klijn JG. et al. T The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-43.
    PubMedGoogle Scholar
  • 42 Bouchet C, Hacene K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048-57.
    CrossrefPubMedGoogle Scholar
  • 43 Mercatante DR, Sazani P, Kole R. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets 2001; 1: 211-30.
    CrossrefPubMedGoogle Scholar
  • 44 Yousef GM, Diamandis EP. Human tissue kallikreins: a new enzymatic cascade pathway. Biol Chem 2002; 383: 1045-57.
    PubMedGoogle Scholar
  • 45 Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102.
    PubMedGoogle Scholar
  • 46 Caballero OL, de Souza SJ, Brentani RR, Simpson AJ. Alternative spliced transcripts as cancer markers. Dis Markers 2001; 17: 67-75.
    CrossrefPubMedGoogle Scholar
  • 47 Obermair A, Schmid BC, Packer LM, Leodolter S, Birner P, Ward BG, Crandon AJ, McGuckin MA, Zeillinger R. Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 2002; 100: 166-71.
    CrossrefPubMedGoogle Scholar
  • 48 Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002; 2: 9-15.
    PubMedGoogle Scholar
  • 49 Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002; 8: 2253-9.
    PubMedGoogle Scholar
  • 50 Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KT, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ. et al. P Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Path 2002; 160: 441-7.
    CrossrefPubMedGoogle Scholar
  • 51 Magklara A, Scorilas A, Katsaros D. et al. Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splicevariants and its prognostic value in ovarian cancer. Clin Cancer Res 2001; 7: 806-11.
    PubMedGoogle Scholar